Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...
Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle claims by the U.S. Securities and Exchange Commission (SEC) ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and ...
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic ...
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...
2d
The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its ...
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...
Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback